臺灣健保癌症用藥事前審查實作指引
1.0.8 - ci-build

臺灣健保癌症用藥事前審查實作指引, published by 衛生福利部中央健康保險署. This guide is not an authorized publication; it is the continuous build for version 1.0.8 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/TWNHIFHIR/pas/ and changes regularly. See the Directory of published versions

Example Observation: 基因資訊

狀態：final

類型：基因資訊 (NHI-補充資訊類別值集#geneInfo)

code：Genetic variant assessment (LOINC#69548-6)

病人：Patient/pat-min

基因檢測日期：2024-05-07

基因檢測代碼：KRAS gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal （ LOINC-基因檢測代碼值集#21702-6）
基因檢測實際結果：KRAS 12 mutation: Not Detected, KRAS 13 mutation: Not Detected, KRAS 61 mutation: Not Detected
基因突變類型：Not detected （ LOINC-基因突變類型值集#LA11883-8）

基因檢測機構：Organization 2023LDTB0002

基因檢測分析結果：基因檢測報告結果

基因臨床判讀結果：Positive (ObservationInterpretationCodes #POS)

基因檢測方法：PCR (LOINC Answer List LL4048-6 #LA26418-6)

基因檢測檢體類型：Specimen/spe-min

基因報告：DocumentReference/doc-gene-min